Screener / SEC EDGAR /CIK 0002014596 /10-K filed Feb 26, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Specialty Outpatient Facilities

Concentra Group Holdings Parent, Inc. CON

Compare with peers Embed

CON among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+13.9%58th of 155 · median +10.5%
Net margin
-4.1%15.3%
9.3%66th of 154 · median 6.8%
Return on equity
-5.2%18.5%
42.7%10th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
11.0%69th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
3.00103rd of 108 · median 0.69

CON and 9 peers, year by year

The 9 Health care companies closest to CON in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
CON Concentra Group Holdings Parent, Inc. FY2025 $2.2B+13.9%-15.4%7.7%9.1%42.3%4.00
ENOV Enovis CORP FY2025 $2.2B+6.7%59.8%−50.0%−52.7%0.9%−79.5%0.87
RDNT RadNet, Inc. FY2025 $2.0B+11.5%-3.0%−0.9%-−1.7%1.00
TFX Teleflex Inc FY2025 $2.0B+17.2%56.2%5.9%−45.4%0.1%−29.0%0.85
PRVA Privia Health Group, Inc. FY2025 $2.1B+22.3%-1.6%1.1%-3.1%-
ICUI ICU Medical Inc FY2025 $2.2B−6.3%36.8%1.9%0.0%4.1%0.0%0.60
EXEL Exelixis, Inc. FY2025 $2.3B+7.0%-37.6%33.7%37.7%36.2%-
MRNA Moderna FY2025 $1.9B−39.9%-−158.1%−145.2%−106.2%−32.6%0.07
QDEL QuidelOrtho Corp FY2025 $2.7B−1.9%-−33.7%−41.5%−3.0%−58.9%1.40
RPRX Royalty Pharma plc FY2025 $2.4B+5.1%-65.6%32.4%-7.9%0.92

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2022 to FY2025 · 10-K XBRL

CONConcentra Group Holdings Parent, Inc.
FY2022 revenue $1.7BFY2023 revenue $1.8BFY2024 revenue $1.9BFY2025 revenue $2.2B FY2022 net margin 9.7%FY2023 net margin 9.8%FY2024 net margin 8.8%FY2025 net margin 7.7% FY2022FY2025
Revenue$2.2B Growth+13.9% Net margin7.7%
ENOVEnovis CORP
FY2022 revenue $1.6BFY2023 revenue $1.7BFY2024 revenue $2.1BFY2025 revenue $2.2B FY2022 net margin −0.9%FY2023 net margin −1.9%FY2024 net margin −39.2%FY2025 net margin −52.7% FY2022FY2025
Revenue$2.2B Growth+6.7% Net margin−52.7%
RDNTRadNet, Inc.
FY2022 revenue $1.4BFY2023 revenue $1.6BFY2024 revenue $1.8BFY2025 revenue $2.0B FY2022 net margin 0.7%FY2023 net margin 0.2%FY2024 net margin 0.2%FY2025 net margin −0.9% FY2022FY2025
Revenue$2.0B Growth+11.5% Net margin−0.9%
TFXTeleflex Inc
FY2022 revenue $2.8BFY2023 revenue $1.7BFY2024 revenue $1.7BFY2025 revenue $2.0B FY2022 net margin 13.0%FY2023 net margin 20.8%FY2024 net margin 4.1%FY2025 net margin −45.4% FY2022FY2025
Revenue$2.0B Growth+17.2% Net margin−45.4%
PRVAPrivia Health Group, Inc.
FY2022 revenue $1.4BFY2023 revenue $1.7BFY2024 revenue $1.7BFY2025 revenue $2.1B FY2022 net margin −0.6%FY2023 net margin 1.4%FY2024 net margin 0.8%FY2025 net margin 1.1% FY2022FY2025
Revenue$2.1B Growth+22.3% Net margin1.1%
ICUIICU Medical Inc
FY2022 revenue $2.3BFY2023 revenue $2.3BFY2024 revenue $2.4BFY2025 revenue $2.2B FY2022 net margin −3.3%FY2023 net margin −1.3%FY2024 net margin −4.9%FY2025 net margin 0.0% FY2022FY2025
Revenue$2.2B Growth−6.3% Net margin0.0%
EXELExelixis, Inc.
FY2022 revenue $1.6BFY2023 revenue $1.8BFY2024 revenue $2.2BFY2025 revenue $2.3B FY2022 net margin 11.3%FY2023 net margin 11.4%FY2024 net margin 24.0%FY2025 net margin 33.7% FY2022FY2025
Revenue$2.3B Growth+7.0% Net margin33.7%
MRNAModerna
FY2022 revenue $19.3BFY2023 revenue $6.8BFY2024 revenue $3.2BFY2025 revenue $1.9B FY2022 net margin 43.4%FY2023 net margin −68.8%FY2024 net margin −110.0%FY2025 net margin −145.2% FY2022FY2025
Revenue$1.9B Growth−39.9% Net margin−145.2%
QDELQuidelOrtho Corp
FY2022 revenue $3.3BFY2023 revenue $3.0BFY2024 revenue $2.8BFY2025 revenue $2.7B FY2022 net margin 16.8%FY2023 net margin −0.3%FY2024 net margin −73.7%FY2025 net margin −41.5% FY2022FY2025
Revenue$2.7B Growth−1.9% Net margin−41.5%
RPRXRoyalty Pharma plc
FY2022 revenue $2.2BFY2023 revenue $2.4BFY2024 revenue $2.3BFY2025 revenue $2.4B FY2022 net margin 1.9%FY2023 net margin 48.2%FY2024 net margin 37.9%FY2025 net margin 32.4% FY2022FY2025
Revenue$2.4B Growth+5.1% Net margin32.4%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2022 to FY2025

Revenue as reported in the 10-K.

20 50 100 FY2022FY2023FY2024FY2025 ENOV: $1.6B, $1.7B, $2.1B, $2.2B ENOV RDNT: $1.4B, $1.6B, $1.8B, $2.0B RDNT TFX: $2.8B, $1.7B, $1.7B, $2.0B TFX PRVA: $1.4B, $1.7B, $1.7B, $2.1B PRVA ICUI: $2.3B, $2.3B, $2.4B, $2.2B ICUI EXEL: $1.6B, $1.8B, $2.2B, $2.3B EXEL MRNA: $19.3B, $6.8B, $3.2B, $1.9B MRNA QDEL: $3.3B, $3.0B, $2.8B, $2.7B QDEL RPRX: $2.2B, $2.4B, $2.3B, $2.4B RPRX CON: $1.7B, $1.8B, $1.9B, $2.2B CON
CON is the bold green line; each peer has its own colour and dash, named at the line's end. Each company's first year in the window is 100, on a log scale: a line twice as high has doubled. A gap is a year with no number. TFX: the line is cut where a later 10-K restates the year before (a spin-off or a merger), so the two years are not the same company.

Sales growth, FY2022 to FY2025

Revenue against the fiscal year before.

−64.4% +92.3% FY2022FY2023FY2024FY2025 ENOV: +9.6%, +9.2%, +23.5%, +6.7% ENOV RDNT: +8.7%, +13.0%, +13.2%, +11.5% RDNT TFX: −0.7%, +6.6%, −0.8%, +17.2% TFX PRVA: +40.4%, +22.2%, +4.7%, +22.3% PRVA ICUI: +73.2%, −0.9%, +5.4%, −6.3% ICUI EXEL: +12.3%, +13.6%, +18.5%, +7.0% EXEL MRNA: +4.3%, −64.4%, −52.7%, −39.9% MRNA QDEL: +92.3%, −8.2%, −7.2%, −1.9% QDEL RPRX: −2.3%, +5.2%, −3.9%, +5.1% RPRX CON: -, +6.6%, +3.4%, +13.9% CON
CON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −64.4% to +92.3%. A gap is a year with no number. A ring marks where a line starts: CON has no earlier 10-K here.

Gross margin, FY2022 to FY2025

Gross profit / revenue.

30.6% 61.0% FY2022FY2023FY2024FY2025 ENOV: 55.6%, 58.0%, 56.0%, 59.8% ENOV TFX: 54.9%, 60.7%, 61.0%, 56.2% TFX ICUI: 30.6%, 32.8%, 34.6%, 36.8% ICUI
CON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 30.6% to 61.0%. A gap is a year with no number.
CompanyFY2022FY2023FY2024FY2025
CON Dec ----
ENOV Dec 55.6%58.0%56.0%59.8%
RDNT Dec ----
TFX Dec 54.9%60.7%61.0%56.2%
PRVA Dec ----
ICUI Dec 30.6%32.8%34.6%36.8%
EXEL Jan ----
MRNA Dec ----
QDEL Dec ----
RPRX Dec ----
Peer median54.9%58.0%56.0%56.2%

Operating margin, FY2022 to FY2025

Operating income / revenue.

−158.1% 65.6% FY2022FY2023FY2024FY2025 ENOV: −4.6%, −3.8%, −36.8%, −50.0% ENOV RDNT: 3.2%, 6.1%, 5.7%, 3.0% RDNT TFX: 17.9%, 15.1%, 6.1%, 5.9% TFX PRVA: −1.4%, 1.2%, 1.0%, 1.6% PRVA ICUI: −1.9%, 1.0%, 1.8%, 1.9% ICUI EXEL: 12.5%, 9.3%, 27.9%, 37.6% EXEL MRNA: 48.9%, −61.9%, −121.9%, −158.1% MRNA QDEL: 25.8%, 4.6%, −70.5%, −33.7% QDEL RPRX: 13.7%, 63.4%, 57.1%, 65.6% RPRX CON: 15.0%, 15.6%, 16.0%, 15.4% CON
CON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −158.1% to 65.6%. A gap is a year with no number.

Net margin, FY2022 to FY2025

Net income / revenue.

−145.2% 48.2% FY2022FY2023FY2024FY2025 ENOV: −0.9%, −1.9%, −39.2%, −52.7% ENOV RDNT: 0.7%, 0.2%, 0.2%, −0.9% RDNT TFX: 13.0%, 20.8%, 4.1%, −45.4% TFX PRVA: −0.6%, 1.4%, 0.8%, 1.1% PRVA ICUI: −3.3%, −1.3%, −4.9%, 0.0% ICUI EXEL: 11.3%, 11.4%, 24.0%, 33.7% EXEL MRNA: 43.4%, −68.8%, −110.0%, −145.2% MRNA QDEL: 16.8%, −0.3%, −73.7%, −41.5% QDEL RPRX: 1.9%, 48.2%, 37.9%, 32.4% RPRX CON: 9.7%, 9.8%, 8.8%, 7.7% CON
CON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −145.2% to 48.2%. A gap is a year with no number.

Free cash flow, FY2022 to FY2025

Cash from operations minus capital spending.

−$4.1B $4.6B FY2022FY2023FY2024FY2025 ENOV: −$161.3M, $12.8M, −$67.2M, $19.9M ENOV TFX: $263.6M, $159.7M, $211.4M, $1.4M TFX PRVA: $47.1M, $80.7M, -, - PRVA ICUI: −$152.4M, $82.3M, $124.7M, $91.8M ICUI EXEL: $334.9M, $292.9M, $671.5M, $875.8M EXEL MRNA: $4.6B, −$3.8B, −$4.1B, −$2.1B MRNA QDEL: $744.4M, $70.9M, −$112.1M, −$83.0M QDEL CON: $228.4M, $169.4M, $210.3M, $197.1M CON
CON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$4.1B to $4.6B. A gap is a year with no number.

FCF margin, FY2022 to FY2025

Free cash flow / revenue.

−125.3% 37.7% FY2022FY2023FY2024FY2025 ENOV: −10.3%, 0.7%, −3.2%, 0.9% ENOV TFX: 9.4%, 9.3%, 12.4%, 0.1% TFX PRVA: 3.5%, 4.9%, -, - PRVA ICUI: −6.7%, 3.6%, 5.2%, 4.1% ICUI EXEL: 20.8%, 16.0%, 31.0%, 37.7% EXEL MRNA: 23.8%, −55.9%, −125.3%, −106.2% MRNA QDEL: 22.8%, 2.4%, −4.0%, −3.0% QDEL CON: 13.2%, 9.2%, 11.1%, 9.1% CON
CON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −125.3% to 37.7%. A gap is a year with no number.

Return on equity, FY2022 to FY2025

Net income / shareholders' equity at the year end.

−79.5% 60.4% FY2022FY2023FY2024FY2025 ENOV: −0.4%, −1.0%, −32.2%, −79.5% ENOV RDNT: 3.2%, 0.5%, 0.3%, −1.7% RDNT TFX: 9.0%, 8.0%, 1.6%, −29.0% TFX PRVA: −1.7%, 4.1%, 2.3%, 3.1% PRVA ICUI: −3.6%, −1.4%, −6.0%, 0.0% ICUI EXEL: 7.3%, 9.2%, 23.2%, 36.2% EXEL MRNA: 43.7%, −34.0%, −32.7%, −32.6% MRNA QDEL: 11.1%, −0.2%, −68.8%, −58.9% QDEL RPRX: 0.4%, 11.3%, 8.3%, 7.9% RPRX CON: 17.0%, 15.5%, 60.4%, 42.3% CON
CON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −79.5% to 60.4%. A gap is a year with no number.

Debt / equity, FY2022 to FY2025

Total debt / shareholders' equity at the year end.

0.00 5.37 FY2022FY2023FY2024FY2025 ENOV: 0.08, 0.14, 0.52, 0.87 ENOV RDNT: 2.56, 1.32, 1.13, 1.00 RDNT TFX: 0.43, 0.41, 0.39, 0.85 TFX PRVA: 0.00, -, -, - PRVA ICUI: 0.79, 0.77, 0.81, 0.60 ICUI MRNA: -, -, 0.00, 0.07 MRNA QDEL: 0.54, 0.48, 0.83, 1.40 QDEL RPRX: 0.75, 0.61, 0.74, 0.92 RPRX CON: -, 0.00, 5.37, 4.00 CON
CON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 5.37. A gap is a year with no number. A ring marks where a line starts: CON, MRNA have no earlier 10-K here.
CompanyFY2022FY2023FY2024FY2025
CON Dec -0.005.374.00
ENOV Dec 0.080.140.520.87
RDNT Dec 2.561.321.131.00
TFX Dec 0.430.410.390.85
PRVA Dec 0.00---
ICUI Dec 0.790.770.810.60
EXEL Jan ----
MRNA Dec --0.000.07
QDEL Dec 0.540.480.831.40
RPRX Dec 0.750.610.740.92
Peer median0.540.550.740.87

EPS (diluted), FY2022 to FY2025

Diluted earnings per share, on today's share count after splits.

−$30.54 $20.12 FY2022FY2023FY2024FY2025 ENOV: −$0.25, −$0.61, −$14.93, −$20.75 ENOV RDNT: $0.17, $0.05, $0.04, −$0.25 RDNT TFX: $7.68, $7.53, $1.48, −$20.25 TFX PRVA: −$0.08, $0.19, $0.11, $0.18 PRVA ICUI: −$3.11, −$1.23, −$4.83, $0.03 ICUI EXEL: $0.56, $0.65, $1.76, $2.78 EXEL MRNA: $20.12, −$12.33, −$9.28, −$7.26 MRNA QDEL: $9.56, −$0.15, −$30.54, −$16.69 QDEL RPRX: $0.10, $2.53, $1.91, $1.78 RPRX CON: $1.60, $1.73, $1.46, $1.30 CON
CON is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$30.54 to $20.12. A gap is a year with no number.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out CON and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: CON's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CON/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.